ImmuPharma plc · LSE:IMM
ImmuPharma — Investor Presentation (June 2017)
30 slides from ImmuPharma's investor presentation, Jun 30, 2017
Slide 1: Developing Innovative Peptides
plc Developing Innovative Peptides Investor Presentation 30 June 2017
Slide 2: Disclaimer
Disclaimer This presentation contains certain statements and may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looki
Slide 3: Management team
Management team Tim McCarthy Dimitri F. Dimitriou Dr Robert Zimmer Chairman Chief Executive Officer Chief Scientific Officer Franco D’Muzio Dr Stéphane Méry Tracy Weimar Lisa Baderoon Non-Exec Director Non-Exec Director VP Ops & Finance Head of Investor Relations .
Slide 4: Today's presentation
Today’s presentation 1. Introduction 2. Recent fundraising history 4. Update on Lupuzor™ Phase III pivotal trial 3. Pipeline summary 5. IR strategy • Lupuzor™ 6. Summary • Nucants • Peptide platform • Vadim Alexandre, Healthcare Analyst at Northland • Overview of ImmuPharma’s investment case Q&A
Slide 5: Company summary
Company summary • Pharma development company listed on AIM since 2006 (LSE:IMM) • Lead drug candidate, LupuzorTM, for the treatment of Lupus, a life threatening autoimmune disease • Phase III pivotal study ongoing • Substantial ‘blockbuster’ market potential • P140 platform with potential to target
Slide 6: Continued value creation
Continued value creation 52p 7.9m Placing L&G, March ’17 New Price Alto & Shares New £4.1m Equity Placing Investors 35p Oct ‘16: 2.8m Placing New New Price Investors £3.5m Vendor Placing & Equity Issue Shares Including L&G 26p Feb ‘16: 32.8m Placing Alto New Price Holding £8.4 million Placing & Subs
Slide 7: Recent IR activities: Jan to June
Recent IR activities : Jan to June Over Over Over 15 40 20 RNS Presentations Interviews Releases & Meetings
Slide 8: Investor conferences
Investor conferences Biotech Biotech Master & Money Capital Investor Show -Feb- -Feb- -April-
Slide 9: Pipeline overview
Oh mmuPharma olen Ue x Pipeline overview Od Treatment of Lupus. Unmet opportunity. Phase III trial ongoing. Potential application in other autoimmune ye Nucants Vv IPP-204106 = Oncology oe Ophthalmology ¥ Lupuzor ia ophthalmology. Phase Ila completed. Potential for Phase II studies in cancer and Age
Slide 10: Dimitri Dimitriou
oe) ImmuPharma OD j@ © Lupuzor™ forigerimod Dimitri Dimitriou
Slide 11: What is Lupus?
What is Lupus? • Lupus is an autoimmune chronic inflammatory disease, sometimes fatal, associated with disorders of the immune system • Unmet market need, due to the lack of safe and effective treatments • Multi-billion sales potential • Varying patient estimates*: • an estimated 5 million people gl
Slide 12: Lupuzor key USP's
Lupuzor™ key USP’s • Novel mechanism that modulates (not blocks) the immune system • Phase IIb demonstrated a significant efficacy in the treatment of Lupus together with outstanding safety • Lupuzor™ granted Fast Track status by the US FDA and approval for pivotal phase III trial under Special Prot
Slide 13: Lupuzor - mechanism of action
Lupuzor™ - mechanism of action Without P140 APC with P140 MHC-peptide- TCR Proinflammatory T cell Cytokines No activation Proinflammatory B cell BCR Cytokines Damaging No autoantibodies autoantibodies Antibody secreting cells
Slide 14: Lupuzor phase IIb final data
Lupuzor™ phase IIb final data Lupuzor™ Benlysta* Duration of treatment 3 months 12 months N=86 N=548 Drop-out rate % 8% / 16% 23% / 25% (active/placebo) % Responder active 62% 43% % Responder placebo 38% 33% p < 0.025 p < 0.025 Clinical impact + 25% + 10% Based on published data: Lupuzor (Zimmer et
Slide 15: Nucants & ELRO SarL
NUCANTS & ELRO SarL Dr Robert Zimmer
Slide 16: Nucants: A new concept
Nucants: A new concept • Peptide that binds with high affinity to nucleolin (nM) • Nucleolin is highly expressed at the surface of dividing cells (cancer cells) • Potential cancer cell targeting tool • Nucants are cytotoxic on their own • Nucants modulate the improper micro-vasculature: • Ameliorate
Slide 17: Nucants: Clinical development
Nucants: Clinical development • Two Phase I studies completed for tolerability and safety • Efficacy Phase II in pancreatic cancer in combination with gemcitabine next steps • Potential to target further cancer indications in the future
Slide 18: Mechanism of Action of N6L (Nucant)
Mechanism of Action of N6L (Nucant) published in ‘Cancer Research’ N6L is the lead compound of the Nucant family The key findings: • Nucleolin inhibition is a new anti-cancer therapeutic strategy that has been shown to dually normalise tumour vasculature and reduce its volume • As a result, it has t
Slide 19: Peptide Platform
PEPTIDE PLATFORM Dr Robert Zimmer
Slide 20: UREkA: The Bordeaux Division
UREkA: The Bordeaux Division
Slide 21: Why Urelix technology?
Why Urelix technology? • Peptides and receptors are fundamental to the body’s function. Present in very limited quantities; important “in vivo” turn- over; importance of control systems (regulation) • Peptides are fragile and can be easily broken down or displaced • Urelix can make peptides more sta
Slide 22: Potential clinical targets
Potential clinical targets The technology is more suited for certain peptides therefore selected diseases a. Cancer (protein/protein interaction) b. Diabetes Type II: 390 m sufferers c. NASH: Non-Alcoholic Steato-Hepatitis* * Globaldata recently valued the potential at 25 bn US$ in 2016 with a doubl
Slide 23: Phase III Trial Update
Phase III Trial Update Tim McCarthy
Slide 24: Lupuzor phase III trial
Lupuzor™ phase III trial • Phase III ongoing – 28 investigator sites • 11 centres in the US • 16 centres in Europe • 1 centre in Mauritius • Simbec-Orion (CRO) experts in Lupus trials • Protocol agreed with the FDA • One year dosing • Protocol similar to that of Phase IIb • n = 200 patients/study •
Slide 25: Lupuzor phase III trial - study highlights
Lupuzor™ phase III trial - study highlights • 200 patients successfully recruited and randomised (dosed) • 293 patients initially screened illustrating the demand from physicians for a new safe and effective treatment for Lupus • Study status as at the end of June 2017 • All 200 patients have passed
Slide 26: Lupuzor phase III key milestones
Lupuzor™ phase III key milestones • US sites open and recruitment commences 2015 • Investigator Meeting • First dosing of US patients • European sites open and recruitment commences 2016 • First European patients dosed • Additional site in Mauritius • Completion of recruitment of 200 patients 2017 •
Slide 27: Investment rationale
Investment rationale • Lupuzor™ is a potential blockbuster asset owned 100% by ImmuPharma • Pivotal phase III trial on track • Awarded Special Protocol Assessment and Fast Track designation by FDA • Competitive efficacy & safety profile • Collaboration partnership with CNRS • P140 platform provides
Slide 28: Analyst: background, investment case, valuation
• Vadim Alexandre, Healthcare Analyst at Northland • Background • Investment case • Valuation
Slide 29: ImmuPharma
OvmmuPharma OA
Slide 30: ImmuPharma plc contact and advisers
ImmuPharma plc 50 Broadway UK Advisers Westminster London SW1H 0RG Nominated Advisor & Broker U.K. Northland Capital Partners Ltd Public Relations & Investor Relations Tel: +44 20 7152 4080 lisa.baderoon@immupharma.com www.immupharma.com Capital Access Group Auditors Nexia Smith & Williamson Solicit